OncoLink Reports from ASCO 2012

OncoLink at ASCO
OncoLink reporters provide in-depth coverage of scientific presentations from the Annual ASCO Meeting.

13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer Presenter: Renata Duchnowska Affiliation: Polish Brain Metastasis Consortium Background Brain metastases (BM) from breast cancer constitute an important part of therapeutic failures and are associated with severe morbidity and mortality. ...
A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes Presenter: Stefan K. Barta, MD Presenter's Affiliation: Albert Einstein College of Medicine, Bronx, NY Background Patients suffering from HIV are at an increased risk of numerous complications, including several types of cancers. Three...
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study Presenter: Mathias J. Rummel MD, PhD Presenter's Affiliation: Universitaetsklinik, Giessen, Germany Background There are about 25,000 new cases of indolent B-cell lymphoma and mantle cell lymphoma per year, with a median overall survival of...
Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma Presenter: Torgrim Tandstad, MD PhD Presenter's Affiliation: St. Olav's Hospital, Trondheim, Norway Background Contralateral tumor (CLT) occurs in 3.5-5% of men diagnosed with non-seminomatous testicular cancer. ITGCNU (intratubular...
BMI, long-term changes in BMI, and risk of cancer mortality in a large cohort study Presenter: Niloofar Taghizadeh Presenter's Affiliation: Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands Background Many studies have found an association between body mass index (BMI) and the risk...
Cluster-randomized trial of early palliative care for patients with metastatic cancer Presenter: Camilla Zimmermann Affiliation: Princess Margaret Hospital, University Health Network, Toronto, ON, Canada Background Patients with metastatic cancer have compromised quality of life (QOL), which tends to worsen towards the end of...
Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome Presenter: Richard Charles Curry, MD Presenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY Background Primary central nervous system lymphoma (PCNSL) is a relatively uncommon variant of extranodal non-Hodgkin...
DeCIDE: A phase III randomized trial of docetaxel, cisplatin, 5-fluorouracil, (TPF) induction chemotherapy in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck Presenter: Ezra E.W. Cohen, MD Presenter's Affiliation: The University of Chicago, Chicago, IL Background Locoregionally advanced head and neck squamous cell carcinoma (H&N SCC) presents clinicians with a challenging scenario with...
Efficacy of the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines in reducing risk of congestive heart failure (CHF) in childhood cancer survivors (CCS) Presenter: F. Lennie Wong, PhD Presenter's Affiliation: City of Hope, Duarte, CA Background Thoracic radiation and chemotherapy increase the risk of cardiovascular disease in survivors of childhood cancer. Previous studies have suggested...
Estrogen plus progestin (E+P) and breast cancer incidence and mortality Presenter: Rowan T. Chlebowski Presenter's Affiliation: Women's Health Initiative, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA Background The Women's Health Initiative (WHI) was a major research...
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41 Presenter: Andre Robidoux Affiliation: National Surgical Adjuvant Breast and Bowel Project and Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada Background Trastuzumab (Herceptin) is a monoclonal antibody directed...
Evaluation of the effect of care at NCI comprehensive cancer centers on disparities in outcome within adolescents and young adults with cancer Presenter: Dr. Can-Lan Sun, PhD on behalf of Julie Anna Wolfson, M.D. Presenter's Affiliation: City of Hope, Duarte, CA Background The National Cancer Institute defines adolescents and young adults (AYAs) with cancer as individuals aged...
GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study Presenter: Rudolf M. Huber, MD, PhD, FCCP Presenter's Affiliation: Medizinische Klinik Innenstadt, München, Germany Background Concurrent chemo-radiotherapy (CT-RT) is considered the standard treatment for patients with stage III NSCLC....
Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study Presenter: Sven Mahner Affiliation: University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany Background The incidence of vulvar cancer is rising, with an increasing number of patients being diagnosed at younger...
Increasing risk of chronic health conditions in aging survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: Gregory T. Armstrong, M.D., MSCE Presenter's Affiliation: St. Jude Children's Research Hospital, Memphis, TN Background While recent advances in pediatric oncology have improved outcomes with more than 80% of children surviving,...
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of SWOG 9346 (INT-0162), an international phase III trial Presenter: Maha Hussain Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Background Continuous androgen deprivation is the standard of care for patients with metastatic hormone sensitive prostate cancer. ...
Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature Presenter: Satomi Yamamoto, MD Presenter's Affiliation: National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan Background About 30% of patients with NSCLC lung cancer present with locally advanced disease. ...
Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) Presenter: Martin J. Van Den Bent, MD, PhD Presenter's Affiliation: Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands Background Each year, more than 15,000 new cases of diffuse gliomas are diagnosed in...
MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial Presenter: Wolfgang Wick Presenter's Affiliation: University Hospital Heidelberg, Heidelberg, Germany Background The incidence of glioblastoma has increased in elderly adults, and more than half of patients are more than 65-years-old....
New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study Presenter: Chaya S. Moskowitz, PhD Presenter's Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY Background With recent improvements in pediatric oncology, modern overall survival rates approach 80% for childhood cancers. ...
Oncologists' and primary care providers' awareness of late effects of cancer treatment: Implications for survivorship care Presenter: Larissa Nekhlyudov, MD, MPH Presenter's Affiliation: Harvard Medical School and Harvard Vanguard Medical Associates, Boston, MA Background Cancer survivorship is on the rise with an estimated 12 million cancer survivors living in...
Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II Presenter: Robert Glynne-Jones, MD Presenter's Affiliation: Mount Vernon Centre for Cancer Treatment, Middlesex, United Kingdom Background Localized anal cancer is typically treated with definitive chemoradiotherapy (CRT). Patients with...
Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial Presenter: Thierry Conroy, MD Presenter's Affiliation: Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France Background Definitive chemoradiotherapy (CRT) is currently the standard of care in patients with unresectable, locally advanced...
Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer Presenter: Keunchil Park, MD, PhD Presenter's Affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea Background About 20% of all lung cancers are small cell lung cancer...
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane Presenter: Kimberly L. Blackwell, MD Presenter's Affiliation: Duke University Medical Center, Durham, NC Background Breast cancer is the most common malignancy affecting women in the United States and Europe. The treatment of breast cancer...
Racial disparities in breast cancer survival Presenter: Jeffrey H. Silber Affiliation: The University of Pennsylvania Background Since the 1970s, breast cancer mortality rates in the U.S. have been higher among African-American women than among Caucasian women. The factors...
Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up Presenter: Kristina Lindemann Affiliation: Akershus University Hospital, Lørenskog, Norway Background There is an ongoing debate regarding the benefit of radiation in patients with early-stage endometrial carcinoma. While there are four...